---
title: "EMERGENe: Phylogenetic framework to estimate bacterial trait emergence and expansion"
id: "medrxiv-1-estimating-emergence-rates-of-epidemiologically-relevant-traits-in-bacteria"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-estimating-emergence-rates-of-epidemiologically-relevant-traits-in-bacteria"
content_type: "clinical_feed_article"
specialty: "Infectious Disease"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1?rss=1"
published_at: "2026-09-14T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# EMERGENe: Phylogenetic framework to estimate bacterial trait emergence and expansion
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-estimating-emergence-rates-of-epidemiologically-relevant-traits-in-bacteria
- **Specialty:** [Infectious Disease](https://medichelpline.com/clinical-feed/infectious-disease.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1?rss=1)
- **Published At:** 2026-09-14T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Genomic surveillance often reports **prevalence** of traits but can miss rapid expansions of newly acquired, transmissible features within genetically and temporally heterogeneous bacterial populations. - The authors introduce **EMERGENe**, a phylogenetic framework that combines ancestral-state reconstruction and analysis of phyletic patterns to quantify dynamics of gained and transmissible traits using time-scaled phylogenies and binary presence data. - EMERGENe identifies independent phyletic events in which a trait is acquired and inherited by descendants, then estimates interpretable **Entry and Emergence rates** that reflect introduction and expansion of trait-specific populations. - The method was validated with phylogenetic simulations across different evolutionary trajectories and population growth dynamics; EMERGENe outperformed simple prevalence at distinguishing rapidly expanding traits from those with slower or no expansion. - EMERGENe was applied to a national genomic surveillance dataset of 3,745 **Shigella sonnei** isolates and detected known acquisitions of resistance to **azithromycin**, **ciprofloxacin**, and third-generation cephalosporins while characterising their emergence dynamics. - Temporal analyses of the S. sonnei dataset showed progressive expansion of ceftriaxone resistance overlapping with decline and replacement of previously widespread azithromycin resistance. - The framework also identified emerging or previously overlooked epidemiologically relevant features, including a recently described phage plasmid and the **qnrS1** gene. - EMERGENe is available on GitHub (https://github.com/gbatbiff/EMERGENe) and the manuscript links underlying data to a related publication; funder declared as UKRI MRC (MR/X000648/1). - The authors report no competing interests and state ethical approvals and participant consents were obtained; the preprint was posted September 14, 2026.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=JzDEuzJJG2Os_0VEZJ.I84f6O0Z2SafQf6j5FVDgFIg-1789457074.8836157-1.2.1.1-OF3PKPEfqoKrhhbNGCg46eDQWJxplEu14Lfzso2YtjaccI20asMpkDlpWg3Nug1Y) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Estimating emergence rates of epidemiologically relevant traits in bacteria with EMERGENe Gherard Batisti Biffignandi, [ View ORCID Profile](http://orcid.org/0009-0008-8488-251X)Kuangyi Charles Wei, Joel Hellewell, Claire Jenkins, [ View ORCID Profile](http://orcid.org/0000-0002-7752-1942)Jukka Corander, John A Lees, Kate S Baker doi: https://doi.org/10.64898/2026.09.10.26362639 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Gherard Batisti Biffignandi 1 Fondazione IRCCS Policlinico San Matteo, Microbiology and Virology Unit, Pavia, Italy / Department of Genetics, University of Cambridge, Cambridge, United Kingdom, CB2 3EH / European Molecular Biology Laboratory, European Bioinformatics Unit, Hinxton; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Gherard%2BBatisti%2BBiffignandi%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Batisti%20Biffignandi%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGherard%2BBatisti%2BBiffignandi%2B) Kuangyi Charles Wei 2 Department of Genetics, University of Cambridge, Cambridge, United Kingdom, CB2 3EH; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kuangyi%2BCharles%2BWei%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Wei%20KC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKuangyi%2BCharles%2BWei%2B) * [ORCID record for Kuangyi Charles Wei](http://orcid.org/0009-0008-8488-251X "Open in new tab") Joel Hellewell 3 European Molecular Biology Laboratory, European Bioinformatics Unit, Hinxton, United Kingdom, CB10 1SA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Joel%2BHellewell%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hellewell%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJoel%2BHellewell%2B) Claire Jenkins 4 Gastrointestinal Bacteria Reference Unit, United Kingdom Health Security Agency, Colindale, London, United Kingdom, NW9 5EQ; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Claire%2BJenkins%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Jenkins%20C&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AClaire%2BJenkins%2B) Jukka Corander 5 University of Oslo Faculty of Medicine: Universitetet i Oslo, Department of Biostatistics, Faculty of Medicine / Parasites and Microbes Program, Wellcome Sanger Institute, Hinxton, United Kingdom, CB10 1SA * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Jukka%2BCorander%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Corander%20J&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJukka%2BCorander%2B) * [ORCID record for Jukka Corander](http://orcid.org/0000-0002-7752-1942 "Open in new tab") John A Lees 3 European Molecular Biology Laboratory, European Bioinformatics Unit, Hinxton, United Kingdom, CB10 1SA; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=John%2BA%2BLees%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Lees%20JA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AJohn%2BA%2BLees%2B) Kate S Baker 2 Department of Genetics, University of Cambridge, Cambridge, United Kingdom, CB2 3EH; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kate%2BS%2BBaker%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Baker%20KS&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKate%2BS%2BBaker%2B) * For correspondence: kb827@cam.ac.uk * [Abstract](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1299500/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1299500/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1299500/1) * [Supplementary material](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.supplementary-material)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_data/node:1299500/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1299500/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1299500/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Genomic surveillance has transformed our ability to identify and track bacterial lineages and epidemiologically relevant traits. However, surveillance approaches are mainly based on prevalence-based measures, which can obscure the dynamics of traits undergoing rapid expansion within genetically and temporally heterogeneous populations. This limitation is particularly relevant for antimicrobial resistance (AMR), where the emergence and subsequent expansion of newly acquired transmissible traits can generate substantial changes in population-level prevalence. Here, we introduce EMERGENe (https://github.com/gbatbiff/EMERGENe), a phylogenetic framework that combines ancestral-state reconstruction and analysis of phyletic patterns to quantify the emergence dynamics of gained and transmissible traits. Using time-scaled phylogenies and binary presence data, EMERGENe identifies independent phyletic events in which a trait is acquired and subsequently inherited by its descendants, and estimates interpretable Entry and Emergence rates that capture the introduction and expansion of trait-specific populations. We evaluated the performance of EMERGENe using phylogenetic simulations across evolutionary trajectories with different population growth dynamics, and applied our framework to a national genomic surveillance dataset comprising 3,745 Shigella sonnei isolates. Across simulated evolutionary scenarios, EMERGENe was superior to prevalence for discriminating traits undergoing rapid population growth from those with slower or no expansion. Applied to S. sonnei, our method detected previously known epidemiological acquisition of resistance to azithromycin, ciprofloxacin and third-generation cephalosporins, while providing information on their underlying emergence dynamics. Temporal analyses also revealed the progressive expansion of ceftriaxone resistance, overlapping with the increasing replacement of previously highly disseminated azithromycin resistance. EMERGENe also detected emerging and overlooked traits, including a recently described epidemiologically relevant phage plasmid and the qnrS1 gene. EMERGENe provides a complementary approach to genomic surveillance by shifting the focus from static trait prevalence towards the evolutionary processes underlying trait emergence and expansion. Thus, EMERGENe provides a robust quantification method for comparison of trait emergence, and by identifying early signals of rapidly emerging traits, also has the potential to improve longitudinal surveillance, facilitating earlier intervention in the onward transmission of AMR in bacterial populations. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present work are contained in the manuscript ## Funder Information Declared UKRI MRC, MR/X000648/1 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.09.13.26362937v1 "Effectiveness of 20-valent pneumococcal conjugate vaccine against pneumococcal pneumonia hospitalizations among U.S. adults: Test-Negative Design")[Next ](https://www.medrxiv.org/content/10.64898/2026.09.13.26362963v1 "Toward Population-Level Brain AVM Screening: Construction and Evaluation of a Two-Step Genetic Risk Model Incorporating Rare Mendelian Variants and a Novel Polygenic Risk Score") Posted September 14, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/14/2026.09.10.26362639.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1#p-5) [Supplementary Material ](https://www.medrxiv.org/content/10.64898/2026.09.10.26362639v1.supplementary-material) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/14/2026.09.10.26362639.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Estimating emergence rates of epidemiologically relevant traits in bacteria with EMERGENe Gherard Batisti Biffignandi, Kuangyi Charles Wei, Joel Hellewell, Claire Jenkins, Jukka Corander, John A Lees, Kate S Baker medRxiv 2026.09.10.26362639; doi: https://doi.org/10.64898/2026.09.10.26362639 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362639v1%26text%3DEstimating%2520emergence%2520rates%2520of%2520epidemiologically%2520relevant%2520traits%2520in%2520bacteria%2520with%2520EMERGENe "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362639v1%26t%3DEstimating%2520emergence%2520rates%2520of%2520epidemiologically%2520relevant%2520traits%2520in%2520bacteria%2520with%2520EMERGENe "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362639v1%26title%3DEstimating%2520emergence%2520rates%2520of%2520epidemiologically%2520relevant%2520traits%2520in%2520bacteria%2520with%2520EMERGENe%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.09.10.26362639v1%26title%3DEstimating%2520emergence%2520rates%2520of%2520epidemiologically%2520relevant%2520traits%2520in%2520bacteria%2520with%2520EMERGENe "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.09.10.26362639) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.09.10.26362639v1&count=horizontal&via=&text=Estimating%20emergence%20rates%20of%20epidemiologically%20relevant%20traits%20in%20bacteria%20with%20EMERGENe&counturl=www.medrxiv.org/content/10.64898/2026.09.10.26362639v1 "Tweet This") ## Subject Area * [Epidemiology ](https://www.medrxiv.org/collection/epidemiology) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (617) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (901) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (331) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4809) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (479) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (415) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (648) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1626) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15936) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1202) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (7043) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (733) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1064) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (5043) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1433) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1761) * [Hematology](https://www.medrxiv.org/collection/hematology) (585) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1344) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16289) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1173) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (668) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (154) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (722) * [Neurology](https://www.medrxiv.org/collection/neurology) (7270) * [Nursing](https://www.medrxiv.org/collection/nursing) (366) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1081) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1241) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1005) * [Oncology](https://www.medrxiv.org/collection/oncology) (3606) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1051) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (397) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (454) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (470) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (707) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1797) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (737) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (766) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psy
## Related Clinical Research

- [Genomic epidemiology and emerging antimicrobial resistance in Salmonella Paratyphi A from Australi](https://medichelpline.com/clinical-feed/medrxiv-13-genomic-epidemiology-and-emerging-antimicrobial-resistance-profiles-of.md)
- [In vitro activity of gepotidacin combinations against Neisseria gonorrhoeae isolates](https://medichelpline.com/clinical-feed/pubmed-42390436.md) (DOI: 10.1128/aac.00059-26)
- [Antimicrobial resistance and whole-genome sequencing of Neisseria gonorrhoeae isolates, Bangrak ST](https://medichelpline.com/clinical-feed/pubmed-42550164.md) (DOI: 10.1093/jac/dkag260)
- [Macrolide-Resistant Bordetella pertussis Detected in Peru During 2025 Outbreak](https://medichelpline.com/clinical-feed/cdc-emerging-infectious-diseases-journal-2-emergence-of-macrolide-resistant-bordetella-pertussis-peru-2025.md)
- [Nasopharyngeal carriage of Streptococcus pneumoniae in vaccinated Brazilian children aged 2–5 years](https://medichelpline.com/clinical-feed/plos-one-9-nasopharyngeal-carriage-of-streptococcus-pneumoniae-in-children-aged-two-to.md)

## Navigation
- [← Back to Infectious Disease Feed](https://medichelpline.com/clinical-feed/infectious-disease.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.